日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies

PR1肽疫苗可诱导特异性免疫,并在髓系恶性肿瘤中产生临床反应。

Qazilbash, M H; Wieder, E; Thall, P F; Wang, X; Rios, R; Lu, S; Kanodia, S; Ruisaard, K E; Giralt, S A; Estey, E H; Cortes, J; Komanduri, K V; Clise-Dwyer, K; Alatrash, G; Ma, Q; Champlin, R E; Molldrem, J J

Activity of 8F4, a T-cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo.

8F4(一种 T 细胞受体样抗 PR1/HLA-A2 抗体)在体内对原发性人类 AML 的活性

Sergeeva A, He H, Ruisaard K, St John L, Alatrash G, Clise-Dwyer K, Li D, Patenia R, Hong R, Sukhumalchandra P, You M J, Gagea M, Ma Q, Molldrem J J

High titer autoantibodies to GM-CSF in patients with AML, CML and MDS are associated with active disease

急性髓系白血病 (AML)、慢性髓系白血病 (CML) 和骨髓增生异常综合征 (MDS) 患者体内高滴度的抗粒细胞-巨噬细胞集落刺激因子 (GM-CSF) 自身抗体与疾病活动性相关。

Sergeeva, A; Ono, Y; Rios, R; Molldrem, J J